Clinical trials: Embryonal Tumor
Glioblastoma Multiforme
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme.
- Trial name
- NCT02619864
- Testing
- AZD2014
- Where
- 4 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Melanoma (Skin Cancer)
ctDNA for Risk Stratification in Melanoma
This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with…
- Trial name
- NCT07531121
- Where
- Denmark
- Volunteers
- 296 people
- Sponsor
- Herlev and Gentofte Hospital
Glioma of Brain, Craniopharyngioma
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
Children with brain tumors who have had radiation therapy are at risk for problems with attention, memory, and problem solving. Such problems may cause difficulty in school and daily life.
- Conditions
- Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
- Trial name
- NCT03194906
- Testing
- Memantine, Cognitive Assessment
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma
POSitron Emission Imaging Using 18F-FDOPA in Neurooncology
18F-FDOPA PET is expensive. It is mandatory therefore to assess its impact on the management of patients with high-grade gliomas in order to provide medico-economic justification for its use.
- Trial name
- POSEIDON (NCT02631655)
- Testing
- impact of device 18F-FDOPA PET on treatment decisions
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Brain and Central Nervous System Tumors, Lymphoma
Melphalan With BBBD in Treating Patients With Brain Malignancies
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Trial name
- NCT00253721
- Testing
- Melphalan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- OHSU Knight Cancer Institute
Melanoma
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
This is a monocentric prospective study. This study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18F-PFPN PET in patients with melanoma and seek independent prognostic factors for…
- Trial name
- NCT05645484
- Testing
- 18F-PFPN, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glioblastoma
Tumor Electric Fields Treatment System for Glioblastoma
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
- Trial name
- NCT04417933
- Testing
- Tumor Electric Fields Treatment System
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Medulloblastoma, Childhood, Cognitive Impairment
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
The efficacy of treatment with metformin for promoting cognitive recovery and brain growth in children/adolescents treated for a brain tumour will be investigated in a multi-site Phase III randomized double-blind…
- Trial name
- Met Med Can (NCT05230758)
- Testing
- Metformin hydrochloride (HCl) 500mg tablet
- Where
- 20 sites in Australia, Canada
- Volunteers
- 140 people
- Sponsor
- Donald Mabbott
Melanoma
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic [ASCI])…
- Trial name
- NCT01149343
- Testing
- Immunotherapeutic GSK2302025A, different formulations
- Where
- 37 sites in Czechia, France and 4 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Sentinel Lymph Node, Melanoma (Skin)
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
The objective of this study is to determine if fluorescence lymphangiography can be used alone to localize sentinel nodes in patients with melanoma or breast cancer.
- Conditions
- Sentinel Lymph Node, Melanoma (Skin), Breast Cancer
- Trial name
- SPYX (NCT03294330)
- Testing
- IC-Green KIT
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Milton S. Hershey Medical Center
Skin Cancer, Complication
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
Mohs micro-graphic surgery (Mohs) is a tissue-sparing, surgical treatment for different types of skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma, lentigo maligna (melanoma).
- Conditions
- Skin Cancer, Complication, Complication of Surgical Procedure, Complication,Postoperative
- Trial name
- NCT06014619
- Testing
- Mohs surgery, Slow Mohs surgery
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University Medical Center
Metastatic Melanoma, Skin Cancer
Study of ADI-PEG 20 in Patients With Advanced Melanoma
This was a phase 1/2, open-label, dose-escalation study of arginine deiminase linked via succinimidyl succinate to polyethylene glycol of 20,000 molecular weight (ADI-PEG 20) in subjects with advanced melanoma.
- Conditions
- Metastatic Melanoma, Skin Cancer, Neoplasm
- Trial name
- NCT00520299
- Testing
- ADI PEG 20
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Ludwig Institute for Cancer Research
Tricuspid Regurgitation, Tricuspid Valve Disease
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who…
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Disease, Carcinoid Syndrome, Carcinoid Heart Disease
- Trial name
- TRICAR (NCT05064514)
- Testing
- Transcatheter Tricuspid Valved Stent Graft
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Queen Mary University of London
Carcinoma, Hepatocellular, Neuroendocrine Tumors
Circulating Tumor Cells and Tumor DNA in HCC and NET
Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.
- Trial name
- NCT02973204
- Testing
- Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus
- Where
- Denmark
- Volunteers
- 167 people
- Sponsor
- University of Aarhus
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Glioblastoma Multiforme
PreOperative Brain Irradiation in Glioblastoma
PreOperative Brain Irradiation in Glioblastoma (POBIG) is a phase I study that will test the safety and feasibility of a single fraction of preoperative radiotherapy in patients with a new radiological diagnosis of glioblastoma…
- Trial name
- POBIG (NCT03582514)
- Testing
- Preoperative brain irradiation (single fraction)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- The Christie NHS Foundation Trust
Melanoma
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
The goals of this study are to 1) assess the safety of recombinant MAGE-A3 protein combined with AS15 Immunological Adjuvant System (recMAGE-A3 + AS15) as an Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) when…
- Trial name
- Mel55 (NCT01425749)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I a dose escalation is performed and the primary objective is the safety of different doses of TLR-dendritic cell (TLR-DC).
- Trial name
- NCT00940004
- Testing
- autologous dendritic cell vaccination
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00641706
- Testing
- vorinostat, therapeutic conventional surgery, bortezomib
- Where
- 214 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Quality of Life
Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement
The aim of the study is to examine the potentials of involving patients with metastatic melanoma in their own care planning through systematic use of patient-reported outcome measures (PROM).
- Trial name
- NCT03163433
- Testing
- Feedback in the consultation
- Where
- Denmark
- Volunteers
- 282 people
- Sponsor
- University of Aarhus